A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)
Recruiting · Phase 2 · NCT07286175
Conditions: Bipolar Disorder
At a glance
- Research payments reported, 2025
- $3,406
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 400
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- Brenipatide (drug), Placebo (drug)
- Dates
- Started 2025-11-24; completion 2027-11
- Results posted
- Not yet
The purpose of this study is to assess the efficacy and safety of brenipatide when administered with standard of care (SoC), compared with placebo plus SoC in delaying the worsening of bipolar disorder symptoms. The trial is divided into three periods as follows: Screening period that will last approximately 1 month, treatment period that will last a minimum of 6 months, and the follow up period that will last approximately 2 months. The duration of study participation may vary and may be shortened if bipolar symptoms worsen or if withdrawal from the study occurs for any reason.
From ClinicalTrials.gov, last updated 2026-11-04. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $3,406 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Northwest Clinical Research Center $3,406
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.